Table 2.

Efficacy by Central Radiographic Assessment.

	All patients N = 339	DLL3-high N = 238	DLL3-positive N = 287
Primary endpoints
Objective response rate, n (%)	42 (12.4)	34 (14.3)	38 (13.2)
(95% CI)	(9.1–16.4)	(10.1–19.4)	(9.5–17.7)
Overall survival, median (mo)	5.6	5.7	5.8
(95% CI)	(4.9–6.1)	(4.9–6.7)	(5.1–6.7)
Secondary endpoints
Duration of objective response, median (mo)	4.0	3.7	3.7
(95% CI)	(3.0–4.2)	(2.9–4.2)	(2.9–4.2)
Progression-free survival, median (mo)	3.5	3.8	3.8
(95% CI)	(3.0–3.9)	(3.2–4.1)	(3.2–4.0)
Disease control rate, n (%)	236 (69.6)	175 (73.5)	206 (71.8)
(95% CI)	(64.4–74.5)	(67.4–79.0)	(66.2–76.9)

Abbreviations: CI, confidence interval; DLL3, delta-like 3 protein; mo, months.